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Presentation and diagnosis
A 66-year-old Caucasian woman without a signi-
ficant past medical history underwent a routine bilat-
eral mammography in October 2001 that showed a
speculated mass in the right breast. Ultrasound
examination of the right breast revealed two sepa-
rate masses (1.7 and 1.4 cm) suggestive of malig-
nancy. A core biopsy showed invasive ductal
carcinoma, and the patient underwent a right lumpec-
tomy with sentinel lymph node dissection that
revealed two separated invasive carcinomas: 1.5 
1.5 and 1.7  1.3 cm, poorly differentiated with
signet ring features, extensive lymphovascular inva-
sion, positive margins in one of the lesions, areas of
in-situ lobular carcinoma, ER, PR, and HER2
with gene amplification by FISH (Ratio of 5.6 for
HER2 amplification adjusted for chromosome 17
polysomy; ratio of greater of 2 indicates amplifica-
tion). One of fifteen axillary lymph nodes was posi-
tive for carcinoma with a 0.2 cm metastatic
implant. Subsequently the patient had a right modi-
fied mastectomy with TRAM reconstruction with no
evidence of residual carcinoma in the breast, and
one in two additional lymph nodes examined were
positive for carcinoma. The tumor marker Ca 15-3
was elevated up to 85 units/ml (normal  32 units/ml).
She was found on staging evaluation (computerized
tomographical (CT) scan, bone scan) to have radio-
graphic findings consistent with mixed lytic–sclerotic
metastasis in the left proximal femur. Follow-up eval-
uation with positron emission tomographical (PET)
scan confirmed intense increase in uptake of F-18
fluorodeoxy-glucose (FDG) within the left femoral
intertrochanteric region, as well as a focus of increased
activity in the right ischial region and the right iliac
crest suspicious for bone metastasis.
In summary, this is a post-menopausal patient
who presented with Stage IV breast carcinoma with
bone metastasis and increased tumor marker Ca
15-3. The tumor biomarkers suggested that the tumor
was estrogen dependent but amplification of HER2
was also present. Besides a mild left hip pain, the
patient was asymptomatic with a performance status
ECOG 0.
Treatment and outcome
The patient was treated initially with radiation to the
left hip to prevent a bone fracture, biphosphonates
to prevent skeletal complications associated with
bone metastasis, and endocrine therapy with an
aromatase inhibitor. The patient received zoledronic
acid and exemestane with decrease in the tumor
marker Ca 15-3 and stabilization in the progression
of the disease for 7 months (Figure 1). The patient
subsequently experienced progression in bone and
she received fulvestrant, a pure estrogen receptor
antagonist, and another aromatase inhibitor, letro-
zole for 5 and 2 months respectively, with progres-
sion of bone disease and significant elevation in the
Ca 15-3 tumor marker up to 520 units/ml. At this point
the patient still had a good performance status,
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without bone pain. Subsequently, the patient received
tamoxifen 20 mg every day and trastuzumab every 
3 weeks. The patient had a dramatic response with
normalization in the tumor marker and stabilization in
the progression of her bone metastatic disease. This
combination was very well tolerated, had no signifi-
cant side effects, and was effective for 9 months when
the tumor showed progression again. The patient then
experienced right hip pain and the bone scan showed
an interval progression in the metastatic disease in
the left femoral neck that correlated with CT findings
of a sclerotic lesion in the same place. There were
other lesions in the sacrum, right acetabulum, right
iliac wing, and vertebral bodies of L5 and S1. The
patient received radiation to the right hip to prevent
an impending fracture with relief in the hip pain.
The patient was informed that the typical man-
agement approach following failure of multiple lines
of endocrine treatment and trastuzumab would be
to continue the trastuzumab and initiate chemother-
apy. We also suggested the alternative of fifth-line
endocrine therapy with high-dose estradiol, 10 mg
every 8 hours, and the patient took that option, based
in quality of life considerations with the outcome indi-
cated in Figure 1. Interestingly, estradiol treatment
rapidly controlled disease progression with normal-
ization in the tumor marker Ca 15-3, and after 9 months
of treatment the patient is asymptomatic with stable
osseous metastatic disease followed with bone and
CT scans. The patient continues receiving monthly
zoledronic acid and her yearly mammograms have
been normal.
Comments
Remarkably, this patient with advanced ER,
HER2 breast cancer, refractory to standard hor-
monal therapies (steroidal and non-steroidal aro-
matase inhibitors, fulvestrant, and tamoxifen),
progressing following trastuzumab treatment in com-
bination with tamoxifen, responded to estradiol ther-
apy as fifth-line treatment without significant side
effects. Although the mechanism responsible for effi-
cacy of estrogen therapy is not completely under-
stood, high doses of estrogen are thought to function
principally by activating apoptotic pathways. Estradiol,
which initially enhanced cell growth and tumor cell
survival, appears to collapse the enhanced survival
systems associated with endocrine-therapy-resistant
disease progression [1]. Our case suggests that this
event may not be impeded by constitutive HER2 sig-
naling, opening the possibility of estradiol therapy in
the setting of ER HER2 FISH disease, even after
trastuzumab treatment.
The paradoxical anti-tumor action of high doses of
synthetic estrogens in the treatment of breast can-
cer has a long history, and has been known since
the 1950s [2]. In the 1970s, Ingle and colleagues
showed in a randomized clinical trial of diethylstilbe-
strol (DES) vs. tamoxifen in post-menopausal women
with advanced breast cancer (n  143), similar
response rates (41% and 33% complete plus partial
response for DES or tamoxifen respectively, P  NS)
and similar progression free survival (142 vs. 171
days for DES or tamoxifen respectively, P  NS) [3].
Toxicity was greater in patients receiving DES, with
9/74 patients (12%) discontinuing therapy solely
because of adverse reactions. Since there was no
statistically significant difference in efficacy and
since tamoxifen was less toxic, tamoxifen was pro-
posed as the preferred agent and as the standard of
care endocrine therapy for breast cancer since the
1970s. However longer-term follow-up this trial sug-
gested an overall survival advantage for the DES
arm renewing interest in high-dose estrogen ther-
apy, particularly as third or fourth-line endocrine
treatment.
Whereas most of the data with high-dose estro-
gen is from patients receiving DES as first-line ther-
apy for advanced disease, patients with previous
exposure to multiple lines of contemporary endocrine
therapy may be hyper-sensitized to estrogen ther-
apy. A Phase II study of DES (5 mg, three times daily)
following exhaustive anti-estrogen and aromatase
inhibitor therapy showed 4/32 complete responses,




























Changes in Ca 15-3 tumor marker during different treat-
ments. Dotted line marks the upper normal limit for Ca 15-3.
In the bottom part is represented the course treatments
the patient has received. Rad: palliative radiation therapy.
However, the use of high-dose estrogen therapy is
associated with breast tenderness, vaginal discharge,
and, more seriously, congestive heart failure, venous
thrombosis and malignant hypercalcemia and so
there remains considerable reluctance to use this
potentially valuable endocrine approach. However
with modern supportive care and careful case selec-
tion these problems are manageable.
Resistance to SERMs, fulvestrant, and aromatase
inhibitors, results from a complex series of changes
that prevent apoptosis and thus enhance cell prolif-
eration and survival. Alterations in several signal
transduction pathways have been described for
tamoxifen resistance, including enhanced activity of
Activating Protein 1 (AP1) and phosphatidylinositol
3-kinase/protein kinase B (PKB or AKT) pathways
and altered expression of protein kinase C, HER2,
and insulin-like growth factor signaling. All of these
events have been linked to the activation of nuclear
factor B (NF-B).
NF-B is a key transcriptional factor for cell growth
and survival. Increased NF-B activity is involved in
drug resistance in breast cancer, and ER represses
NF-B activity in the presence of estradiol. Estradiol
binds to ER, and the estradiol–ER complex sup-
presses NF-B activity by inhibiting the binding of
NF-B to DNA or by competing with p300/CBP, inde-
pendent of new protein synthesis. The decreased
NF-B activity induced by estradiol should increase
the number of cells undergoing apoptosis [1].
Song and colleagues provided an important clue
that it may be the Fas/FasL system which induces
apoptosis in response to estrogen. They observed
that in some estrogen deprived ER-positive breast
cancer cells, apoptosis occurs with low estrogen
concentrations, by enhancing activation of the Fas
receptor [5]. This hypothesis has been extended to
tamoxifen and raloxifene-stimulated breast cancer
cells in vivo and in vitro [4]. Simultaneously, estradiol
initiates the synthesis of the Fas receptor and the
activation of caspase-8 from procaspase-8 to induce
apoptosis. The result is that tumors previously
exposed to exhaustive anti-estrogen therapies rap-
idly regress in vivo in response to low physiologic
concentrations of estradiol (83–96 pg/ml) within the
post-menopausal range. In addition, high doses of
estrogens reduce plasma levels of insulin growth
factor (IGF), which act in concert to promote the sur-
vival of breast cancer cells [6]. Preclinical models
also implicate a role for IGF-2 in response to high-
dose estrogen [7].
High-dose estrogens should be considered only
in post-menopausal breast cancer patients because
this option is ineffective before menopause [2]. DES
is difficult to obtain in the USA, and a comparable
choice is estradiol, 2 mg tablets. The recommended
dose is 30 mg/day in fractionated doses. Important
questions that remain are if it is possible to achieve
the same clinical results with lower estrogen doses,
and if the response to therapeutic estrogen reacti-
vates response to anti-estrogen therapy, so treat-
ments can be cycled. We are currently conducting a
randomized Phase 2 trial of 6 mg vs. 30 mg of estra-
diol for women with advanced breast cancer refrac-
tory to aromatase inhibitors. As a consequence of our
experience in this case we are amending the proto-
col to allow patients who have received trastuzumab
in combination with either an aromatase inhibitor or
tamoxifen.
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